# # # #
A class of diabetes drugs called GLP-1 receptor agonists have exhibited neuroprotective properties in models of Parkinson’s, and a Phase IIb clinical trial produced encouraging.
This research has led to a number of parties to start investigating new and old GLP-1 receptor agonists for their potential to slow the progression of Parkinson’s.
Recently, the results of a second Phase II clinical trial investigating a GLP-1 agonist were announced. The agonist being tested was liraglutide.
In today’s post, we will discuss what GLP-1 receptor agonists are, what research has been conducted in PD, and look at the recent clinical trial announcement.
# # # #
The name “Golden Goose Award” doesn’t really conjure images of an inspirational kind of accomplishment. It does not suggest the same kind of gravitas that the Nobel prize carries.
In fact, it sounds rather comical: The golden goose award? Sounds like a children’s book writers award.
The Award was originally established in 2012 with the goal of celebrating researchers whose seemingly odd or obscure federally funded research turned out to have a significant and positive impact on society as a whole.
And despite the name, it is a very serious award – past Nobel prize winners (such as Roger Tsien, David H. Hubel, and Torsten N. Wiesel) are among the awardees.
In 2013, it was awarded to Dr John Eng, an endocrinologist from the Bronx VA Hospital.
Dr John Eng. Source: Health.USnews
What did Dr Eng do to deserve the award?
Continue reading “A rising tide with liraglutide”
Speeding up the clinical development process is a shared goal across many medical conditions (not just Parkinson’s and neurodegeneration), and there are many different approaches to achieving this that are being explored.
Some of these approaches could be considered to be bordering on the unethical, but there are aspects of their structure and design that are still worthy of academic discussion and consideration.
One example is a crowd-funded cancer clinical trial called iCancer.
In today’s post, we will discuss the iCancer project.
Over the Christmas period, in addition to spending the required amount of time with family and friends, I fell down a rabbit hole.
Before the festive season, I had been exploring different designs of clinical trials to see what had been given serious academic consideration and thought.
I was particularly intrigued with the ‘pay-to-play’ model (in which patients pay to be part of a study). This model has fallen into disgrace due to abuse by unscrupulous individuals profiting off untested, experimental therapies being targeted towards desperate patients.
To be clear: it is utterly unethical for “for-profit” clinics to be selling access to experimental procedures if there is no proof of efficacy (and this is particularly true for the stem cell clinics).
But I was interested in exploring if anyone had actually explored this type of clinical study design or aspects of it in the academic sense as a means of speeding things up.
In my role as a research co-ordinator for a Parkinson’s charity, I have been lucky enough to meet and get to know some folks who are absolute fountains of knowledge and wisdom when it comes to all things related to clinical trial design. And I just straight up asked some of these individuals if anyone had ever given serious academic thought to the ‘pay-to-play’ model?
I recieved an interesting collection of answers – all erring on the side of extreme caution, with some taking a “are you %#@&£$ serious” tone – and I suspect that any reputation I might have had with those individuals is now dented (such is the taint of pay-to-play).
But one individual – perhaps in an effort to reorient a foolish, but hungry mind – pointed me towards a possibly better approach.
It is being proposed by a group called iCancer.
What is iCancer?
Continue reading “A plutocratic proposal: iCancer”
A reader recently asked for an explanation of some recent research regarding diabetes and Parkinson’s.
You see, a significant proportion of the Parkinson’s community have glucose intolerance issues and some live with the added burden of diabetes. That said, the vast majority of diabetics do not develop PD. Likewise, the vast majority of people with Parkinson’s do not have a diagnosis of diabetes.
There does appear to be a curious relationship between Parkinson’s and diabetes, with some recent research suggests that this association can be detrimental to the course of the condition.
In today’s post we will look at what what diabetes is, consider the associations with Parkinson’s, and we will discuss the new research findings.
Foreman and Ali. Source: Voanews
1974 was an amazing year.
On October 30th, the much-hyped heavyweight title match – the ‘Rumble in the Jungle’ – between George Foreman and Muhammad Ali took place in Kinshasa, Zaire (Democratic Republic of the Congo).
Stephen King. Source: VanityFair
A 26-year-old author named Stephen King published his debut novel, “Carrie” (April 5, with a first print-run of just 30,000 copies).
Lucy. Source: Youtube
The fossil remains of a 3.2 million years old hominid skeleton was discovered in Ethiopia (November 24th). It was named ‘Lucy’ – after the song “Lucy in the Sky with Diamonds” by The Beatles which was played repeatedly in the expedition camp the evening after the team’s first day of work on the site (Source).
And Richard Nixon becomes the first US president to resign from office (August 9th).
President Richard Nixon. Source: Fee
In addition to all of this, in December of 1974, a small study was published in the Journal of Chronic Diseases.
It dealt with Parkinson’s and it presented a rather startling set of findings:
Continue reading “Diabetes and Parkinson’s”